Janusitin M Tablet 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceuticals Co., Ltd.
MFDS item code 202200116 · Approved 2022.01.06
Improvement of blood glucose control in type 2 diabetes mellitus
This medication is a combination treatment primarily used to help control blood sugar levels in patients with type 2 diabetes, administered alongside dietary and exercise therapies. It is indicated for use when initial treatment as monotherapy is insufficient, when blood glucose control is inadequate with monotherapy of metformin or sitagliptin, or when replacing the combination therapy of the two drugs. Furthermore, it can be used in conjunction with metformin and sulfonylureas, metformin and thiazolidinediones, or in cases where blood glucose control is challenging with insulin and metformin, to effectively manage blood sugar levels. These various combination therapies provide optimal blood sugar control tailored to individual patients. Thus, this drug improves blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who must not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who must not take this medicine under Precautions for Use).
This medication is a diabetes treatment that contains both sitagliptin and metformin. Firstly, there is a possibility of allergic reactions occurring while taking this medication, so if symptoms such as rash, hives, shortness of breath, or swelling of the face, lips, tongue, or throat appear, immediately stop taking the drug and consult a physician. Additionally, acute pancreatitis may occur, so if you experience abdominal pain, nausea, vomiting, or severe abdominal pain, seek medical attention immediately. This drug should not be given to patients with severely impaired kidney function, dehydration, severe infections, heart failure, or acute conditions that can affect kidney function, such as acute myocardial infarction. If iodine contrast agents are to be used during tests, this medication should be withheld for a certain period before and after the test, and only restarted after confirming normal kidney function. Women who are pregnant or may become pregnant, and nursing mothers should not take this medication. There is a risk of lactic acidosis, a serious metabolic disturbance, so if you experience symptoms like shortness of breath, muscle pain, weakness, abdominal pain, or changes in consciousness, you should go to the hospital immediately. Also, hypoglycemia may occur, so extra caution must be taken if meals are skipped or irregular, with excessive exercise, or when used in combination with other antidiabetic medications. This drug should be used cautiously or avoided in patients with liver impairment, severe infections, malnutrition, dehydration, severe diarrhea, or vomiting. Regular monitoring of blood glucose, kidney function, and vitamin B12 levels should be performed to ensure safety. Before surgery, this medication should be stopped for more than 48 hours, and can be resumed only after kidney function has recovered post-surgery. Finally, it is advisable to avoid alcohol consumption during this treatment, and consult a doctor or pharmacist if you are taking other medications, as drug interactions may occur.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture, and it is safe to store at room temperature between 1 to 30 degrees Celsius. Therefore, to maintain the effectiveness of the medicine, avoid storing it in direct sunlight or in extremely hot or cold locations.
Bright pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Korea Pavis Pharmaceuticals Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.